FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Andrew Grigg

Research Profile

Disorders

Procedures

Concepts & Ideas

Chemicals & Drugs

Co-author Network

Publications

TOP 3
Michelle R Ananda-Rajah; Andrew Grigg; Monica A Slavin
Making sense of posaconazole therapeutic drug monitoring: a practical approach.
Harry Iland; John Moore; John Reynolds; Michael Seldon; John F Seymour; Shane G Supple; Jeff Szer; John Taper; Kerry Taylor; Campbell Tiley; John Bashford; Kenneth F Bradstock; Peter Browett; Alberto Catalano; Marnie Collins; Juliana Di Iulio; Robin Filshie; Frank Firkin; Andrew Grigg; Mark Hertzberg; Amanda Hugman
All-trans-retinoic acid, idarubicin, and IV arsenic trioxide as initial therapy in acute promyelocytic leukemia (APML4).
Prahlad Ho; Peter Sherman; Andrew Grigg
Intermittent granulocyte colony-stimulating factor maintains dose intensity after ABVD therapy complicated by neutropenia.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Andrew Grigg (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2012: Michelle R Ananda-Rajah; Andrew Grigg; Monica A Slavin
Making sense of posaconazole therapeutic drug monitoring: a practical approach.
Current opinion in infectious diseases 2012;25(6):605-11.
2012: Harry Iland; John Moore; John Reynolds; Michael Seldon; John F Seymour; Shane G Supple; Jeff Szer; John Taper; Kerry Taylor; Campbell Tiley; John Bashford; Kenneth F Bradstock; Peter Browett; Alberto Catalano; Marnie Collins; Juliana Di Iulio; Robin Filshie; Frank Firkin; Andrew Grigg; Mark Hertzberg; Amanda Hugman
All-trans-retinoic acid, idarubicin, and IV arsenic trioxide as initial therapy in acute promyelocytic leukemia (APML4).
Blood 2012;120(8):1570-80; quiz 1752.
2012: Prahlad Ho; Peter Sherman; Andrew Grigg
Intermittent granulocyte colony-stimulating factor maintains dose intensity after ABVD therapy complicated by neutropenia.
European journal of haematology 2012;88(5):416-21.
2012: Harry Iland; John Reynolds; John Seymour; Francisca Springall; Shane Supple; Kerry Taylor; Juliet Ayling; Kenneth F Bradstock; Tim Brighton; Peter Browett; Paul Cannell; Alberto Catalano; John Catalano; Li Chong; Marnie Collins; Sandra Deveridge; Juliana Di Iulio; Andrew Grigg; Mark Hertzberg; Noemi Horvath
Results of the APML3 trial incorporating all-trans-retinoic acid and idarubicin in both induction and consolidation as initial therapy for patients with acute promyelocytic leukemia.
Haematologica 2012;97(2):227-34.
2012: Jamie P Nourse; Huyen Tran; Gillian Wright; Andrew Grigg; Rod Lea; Paula Marlton; Tim Brighton; John Catalano; Pauline Crooks; Maher K Gandhi
The KIR2DS2/DL2 genotype is associated with adult persistent/chronic and relapsed immune thrombocytopenia independently of FCGR3a-158 polymorphisms.
Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis 2012;23(1):45-50.
2011: Andrew Wirth; Andrew Grigg; Max Wolf; David Goldstein; Carol Johnson; Sidney Davis; Gaelle Dutu; Poppy Kypreos; Carole Smith; Andrew Kneebone; Mark Herzberg; David Joseph; John Catalano; Daniel Roos; Janey Stone; John Reynolds
Risk and response adapted therapy for early stage Hodgkin lymphoma: a prospective multicenter study of the Australasian Leukaemia and Lymphoma Group/Trans-Tasman Radiation Oncology Group.
Leukemia & lymphoma 2011;52(5):786-95.
2010: Andrew Grigg; M Brown; Jeff Szer
Durable resolution of recurrent microvascular small bowel ischaemia and severe abdominal pain by eculizumab in paroxysmal nocturnal haemoglobinuria.
Internal medicine journal 2010;40(11):794-5.
2010: Michael Dickinson; Rosemary Hoyt; Andrew W Roberts; Andrew Grigg; John F Seymour; H Miles Prince; Jeff Szer; David Ritchie
Improved survival for relapsed diffuse large B cell lymphoma is predicted by a negative pre-transplant FDG-PET scan following salvage chemotherapy.
British journal of haematology 2010;150(1):39-45.
2010: Dishan H Gunawardana; Andrew Grigg
Use of 18F-fluorodeoxyglucose positron emission tomography to change management and assess response to therapy in post-transplant extramedullary relapse of acute myeloid leukaemia.
Internal medicine journal 2010;40(6):466-7.
2010: Anna Kalff; Claire Dowsing; Andrew Grigg
The impact of a regular erythrocytapheresis programme on the acute and chronic complications of sickle cell disease in adults.
British journal of haematology 2010;149(5):768-74.
2010: Eddie W F Lau; Katharine J Drummond; Robert E Ware; Elizabeth Drummond; Annette Hogg; Gail Ryan; Andrew Grigg; Jason Callahan; Rodney J Hicks
Comparative PET study using F-18 FET and F-18 FDG for the evaluation of patients with suspected brain tumour.
Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia 2010;17(1):43-9.
2009: K J Lu; Andrew Grigg; D Leslie; M Finlay; Joseph Sasadeusz
Mycobacterium genavense duodenitis following allogeneic peripheral blood stem cell transplantation.
Transplant infectious disease : an official journal of the Transplantation Society 2009;11(6):534-6.
2009: Sanjay Theodore; Matthew Liava'a; Phillip Antippa; Rochelle Wynne; Andrew Grigg; Monica Slavin; James Tatoulis
Surgical management of invasive pulmonary fungal infection in hematology patients.
The Annals of thoracic surgery 2009;87(5):1532-8.
2009: Ashley Ng; Patricia Servadei; Annabel Tuckfield; Anna Friedhuber; Andrew Grigg
Resolution of platelet function defects with imatinib therapy in a patient with chronic myeloid leukaemia in chronic phase.
Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis 2009;20(1):81-3.
2009: N Frawley; Ashley Ng; Kathy Nicholls; S Cohney; C Hogan; Andrew Grigg
Thrombotic thrombocytopenic purpura is associated with a high relapse rate after plasma exchange: a single-centre experience.
Internal medicine journal 2009;39(1):19-24.
2008: Timothy P Hughes; Susan Branford; Deborah L White; John Reynolds; Rachel Koelmeyer; John F Seymour; Kerry Taylor; Chris Arthur; Anthony P Schwarer; James Morton; Julian Cooney; Michael F Leahy; Philip Rowlings; John Catalano; Mark Hertzberg; Robin Filshie; Anthony K Mills; Keith Fay; Simon Durrant; Henry Januszewicz; David Joske; Craig Underhill; Scott Dunkley; Kevin Lynch; Andrew Grigg
Impact of early dose intensity on cytogenetic and molecular responses in chronic- phase CML patients receiving 600 mg/day of imatinib as initial therapy.
Blood 2008;112(10):3965-73.
2008: Helen Fairweather; Annabel Tuckfield; Andrew Grigg
Abbreviated dose rituximab for immune-mediated hematological disorders.
American journal of hematology 2008;83(7):554-7.
2008: Sarr Gill; Andrew Grigg; Anoren Grigg; Jeff Szer; David Ritchie
Long-term toxicity of allogeneic stem cell transplantation in fludarabine-refractory chronic lymphocytic leukemia.
Leukemia & lymphoma 2008;49(5):896-901.
2008: Steven Lane; Russell Saal; Peter Mollee; Mark Jones; Andrew Grigg; Kerry Taylor; John Seymour; Glen Kennedy; Bronwyn Williams; Karen Grimmett; Vanessa Griffiths; Devinder Gill; Matthew Hourigan; Paula Marlton
A >or=1 log rise in RQ-PCR transcript levels defines molecular relapse in core binding factor acute myeloid leukemia and predicts subsequent morphologic relapse.
Leukemia & lymphoma 2008;49(3):517-23.
2008: Andrew Grigg; M Slavin
Minimizing the risk of recurrent or progressive invasive mold infections during stem cell transplantation or further intensive chemotherapy.
Transplant infectious disease : an official journal of the Transplantation Society 2008;10(1):3-12.
2007: Susan Branford; John F Seymour; Andrew Grigg; Chris Arthur; Zbigniew Rudzki; Kevin Lynch; Timothy Hughes
BCR-ABL messenger RNA levels continue to decline in patients with chronic phase chronic myeloid leukemia treated with imatinib for more than 5 years and approximately half of all first-line treated patients have stable undetectable BCR-ABL using strict sensitivity criteria.
Clinical cancer research : an official journal of the American Association for Cancer Research 2007;13(23):7080-5.
2007: Deborah White; Verity A Saunders; Andrew Grigg; Chris Arthur; Robin Filshie; Michael F Leahy; Kevin Lynch; L Bik To; Timothy Hughes
Measurement of in vivo BCR-ABL kinase inhibition to monitor imatinib-induced target blockade and predict response in chronic myeloid leukemia.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2007;25(28):4445-51.
2007: Simon He; Andrew Roberts; David Ritchie; Andrew Grigg
Graft-versus-lymphoma effect in progressive hepatosplenic gamma/delta T-cell lymphoma.
Leukemia & lymphoma 2007;48(7):1448-50.
2006: Geoffrey R Hill; Edward S Morris; Madonna Fuery; Cheryl Hutchins; Jason Butler; Andrew Grigg; Andrew Roberts; Kenneth F Bradstock; Jeff Szer; Glen Kennedy; James Morton; Simon Durrant
Allogeneic stem cell transplantation with peripheral blood stem cells mobilized by pegylated G-CSF.
Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 2006;12(6):603-7.
2006: M Hertzberg; Andrew Grigg; David Gottlieb; J Szer; A Roberts; R Hoyt; G Huang; Kenneth F Bradstock
Reduced-intensity allogeneic haemopoietic stem cell transplantation induces durable responses in patients with chronic B-lymphoproliferative disorders.
Bone marrow transplantation 2006;37(10):923-8.
2006: N Murphy; M Diviney; Jeff Szer; Peter Bardy; Andrew Grigg; R Hoyt; B King; L Macgregor; Rhonda Holdsworth; James McCluskey; Brian D Tait
Donor methylenetetrahydrofolate reductase genotype is associated with graft-versus-host disease in hematopoietic stem cell transplant patients treated with methotrexate.
Bone marrow transplantation 2006;37(8):773-9.
2005: Deborah White; Verity A Saunders; A Bruce Lyons; Susan Branford; Andrew Grigg; L Bik To; Timothy Hughes
In vitro sensitivity to imatinib-induced inhibition of ABL kinase activity is predictive of molecular response in patients with de novo CML.
Blood 2005;106(7):2520-6.
2005: Andrew Spencer; N Horvath; John Gibson; H M Prince; Richard Herrmann; John Bashford; David Joske; Andrew Grigg; J McKendrick; I Prosser; Raymond Lowenthal; Sandra Deveridge; K Taylor
Prospective randomised trial of amifostine cytoprotection in myeloma patients undergoing high-dose melphalan conditioned autologous stem cell transplantation.
Bone marrow transplantation 2005;35(10):971-7.
2005: A Wirth; H M Prince; M Wolf; J M Stone; J Matthews; J Gibson; C Macleod; Jeff Szer; Andrew Grigg; Bik To; D Roos; Anthony P Schwarer; S Davis
Optimal scheduling to reduce morbidity of involved field radiotherapy with transplantation for lymphomas: a prospective Australasian Leukaemia and Lymphoma Group Study.
Bone marrow transplantation 2005;35(3):291-8.
2004: PN Mollee; C Arthur; T Hughes; H Januszewicz; Andrew Grigg; Kenneth F Bradstock; Max Wolf; J Gibson; Anthony P Schwarer; A Spencer; Peter Browett; T Hawkins; M Seldon; R Herrmann; A Watson; John F Seymour; N Martin; S Shina; C Low; S Wright; Robyn Rodwell; J Coulston; J Morton; H Blacklock; D Taylor; K M Taylor
Interferon-alpha-2b and oral cytarabine ocfosfate for newly diagnosed chronic myeloid leukaemia.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2004;15(12):1810-5.
2004: Susan Branford; Zbigniew Rudzki; Ian Parkinson; Andrew Grigg; Kerry Taylor; John F Seymour; Simon Durrant; Peter Browett; Anthony P Schwarer; Chris Arthur; John Catalano; Michael F Leahy; Robin Filshie; Kenneth F Bradstock; Richard Herrmann; David Joske; Kevin Lynch; Timothy Hughes
Real-time quantitative PCR analysis can be used as a primary screen to identify patients with CML treated with imatinib who have BCR-ABL kinase domain mutations.
Blood 2004;104(9):2926-32.
2004: Andrew Grigg; David Ritchie
Graft-versus-lymphoma effects: clinical review, policy proposals, and immunobiology.
Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 2004;10(9):579-90.
2004: Karin Thursky; G Byrnes; Andrew Grigg; Jeff Szer; Monica Slavin
Risk factors for post-engraftment invasive aspergillosis in allogeneic stem cell transplantation.
Bone marrow transplantation 2004;34(2):115-21.
2004: S J Morgan; John F Seymour; Andrew Grigg; Jane P Matthews; H Miles Prince; Max M Wolf; E Henry Januszewicz
Predictive factors for successful stem cell mobilization in patients with indolent lymphoproliferative disorders previously treated with fludarabine.
Leukemia 2004;18(5):1034-8.
2004: Paul L Mitchell; Russell L Basser; M Chipman; Andrew Grigg; R Mansfield; Jonathan Cebon; Ian D Davis; F Appia; M Green
A phase II study of escalated-dose docetaxel with granulocyte colony-stimulating factor support in patients with advanced breast cancer.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2004;15(4):585-9.
2004: Charles G Mullighan; Sue Heatley; Kathleen V Doherty; Ferenc Szabo; Andrew Grigg; Timothy Hughes; Anthony P Schwarer; Jeff Szer; Brian D Tait; Bik To; Peter Bardy
Non-HLA immunogenetic polymorphisms and the risk of complications after allogeneic hemopoietic stem-cell transplantation.
Transplantation 2004;77(4):587-96.
2004: Andrew Grigg; Niall Tubridy; Jeff Szer; P Mitchell; Helmut Butzkueven; Peter Shuttleworth; Trevor J Kilpatrick
Cladribine followed by autologous stem-cell transplantation in progressive multiple sclerosis.
Internal medicine journal 2004;34(1-2):66-9.
2003: Susan Branford; Zbigniew Rudzki; A Harper; Andrew Grigg; Kerry Taylor; Simon Durrant; Chris Arthur; Peter Browett; Anthony P Schwarer; D Ma; John F Seymour; Kenneth F Bradstock; David Joske; Kevin Lynch; Insa Gathmann; Timothy P Hughes
Imatinib produces significantly superior molecular responses compared to interferon alfa plus cytarabine in patients with newly diagnosed chronic myeloid leukemia in chronic phase.
Leukemia 2003;17(12):2401-9.
2003: Linda Mileshkin; James J Biagi; Paul Mitchell; Craig Underhill; Andrew Grigg; Richard Bell; Joe McKendrick; Peter Briggs; John F Seymour; Kate Lillie; Jennifer G Smith; Jerome B Zeldis; H Miles Prince
Multicenter phase 2 trial of thalidomide in relapsed/refractory multiple myeloma: adverse prognostic impact of advanced age.
Blood 2003;102(1):69-77.
2003: Susan Branford; Zbigniew Rudzki; Sonya Walsh; Ian Parkinson; Andrew Grigg; Jeff Szer; Kerry Taylor; Richard Herrmann; John F Seymour; Chris Arthur; David Joske; Kevin Lynch; Timothy Hughes
Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis.
Blood 2003;102(1):276-83.
2003: Kritika Chaiwatanatorn; Newton Lee; Andrew Grigg; Robin Filshie; Frank Firkin
Delayed-onset neutropenia associated with rituximab therapy.
British journal of haematology 2003;121(6):913-8.
2003: Chi-hung Hui; K Y Goh; D White; Susan Branford; Andrew Grigg; John F Seymour; Yiu Lam Kwan; Sonya Walsh; R Hoyt; Annette Trickett; B Rudzki; D D F Ma; L Bik To; Timothy P Hughes
Successful peripheral blood stem cell mobilisation with filgrastim in patients with chronic myeloid leukaemia achieving complete cytogenetic response with imatinib, without increasing disease burden as measured by quantitative real-time PCR.
Leukemia 2003;17(5):821-8.
2003: Paul L Mitchell; Russell L Basser; M Chipman; Andrew Grigg; Jonathan Cebon; Ian D Davis; John Zalcberg; S Ng; F Appia; M Green
A phase I dose-escalation study of docetaxel with granulocyte colony-stimulating factor support in patients with solid tumours.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2003;14(5):788-94.
2003: C McNamara; Andrew Grigg; J Szer; A Roberts; L Campbell; R Hoyt; K Lynch; Surender Juneja
Morphological effects of imatinib mesylate (STI571) on the bone marrow and blood of patients with Philadelphia chromosome (Ph) positive chronic myeloid leukaemia.
Clinical and laboratory haematology 2003;25(2):119-25.
2002: Graham M Mead; Matthew R Sydes; Jan Walewski; Andrew Grigg; C S Hatton; N Pescosta; C Guarnaccia; M S Lewis; JJ McKendrick; Sally P Stenning; D Wright; P Norbert
An international evaluation of CODOX-M and CODOX-M alternating with IVAC in adult Burkitt's lymphoma: results of United Kingdom Lymphoma Group LY06 study.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2002;13(8):1264-74.
2002: Christopher McNamara; Surender Juneja; M Wolf; Andrew Grigg
Portal or hepatic vein thrombosis as the first presentation of a myeloproliferative disorder in patients with normal peripheral blood counts.
Clinical and laboratory haematology 2002;24(4):239-42.
2002: Trevor J Kilpatrick; Helmut Butzkueven; Andrew Grigg
Prospects for stem cell transplantation in multiple sclerosis.
Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia 2002;9(4):361-7.
2002: Charles G Mullighan; Sue Heatley; Kathleen V Doherty; Ferenc Szabo; Andrew Grigg; Timothy P Hughes; Anthony P Schwarer; Jeff Szer; Brian D Tait; L Bik To; Peter Bardy
Mannose-binding lectin gene polymorphisms are associated with major infection following allogeneic hemopoietic stem cell transplantation.
Blood 2002;99(10):3524-9.
2002: Susan Branford; Zbigniew Rudzki; Sonya Walsh; Andrew Grigg; Chris Arthur; Kerry Taylor; Richard Herrmann; Kevin P Lynch; Timothy P Hughes
High frequency of point mutations clustered within the adenosine triphosphate-binding region of BCR/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistance.
Blood 2002;99(9):3472-5.
2001: J Sasadeusz; H Kelly; Jeff Szer; A P Schwarer; H Mitchell; Andrew Grigg
Abnormal cervical cytology in bone marrow transplant recipients.
Bone marrow transplantation 2001;28(4):393-7.
2001: Brian D Tait; R Maddison; James McCluskey; S Deayton; Sue Heatley; S Lester; Peter Bardy; Jeff Szer; Andrew Grigg; A Spencer; Anthony P Schwarer; Rhonda Holdsworth
Clinical relevance of the minor histocompatibility antigen HA-1 in allogeneic bone marrow transplantation between HLA identical siblings.
Transplantation proceedings 2001;33(1-2):1760-1.
2001: Andrew Grigg; K Kannan; A P Schwarer; A Spencer; J Szer
Chemotherapy and granulocyte colony stimulating factor-mobilized blood cell infusion followed by interferon-alpha for relapsed malignancy after allogeneic bone marrow transplantation.
Internal medicine journal 2001;31(1):15-22.
2000: G Chong; G Byrnes; Jeff Szer; Andrew Grigg
Extramedullary relapse after allogeneic bone marrow transplantation for haematological malignancy.
Bone marrow transplantation 2000;26(9):1011-5.
2000: Andrew Grigg; K Clarke; Jeff Szer
Prolonged disease-free survival after autografting for chemosensitive non-bulky low grade non-Hodgkin's Lymphoma.
Leukemia & lymphoma 2000;39(3-4):283-90.
2000: R Hoyt; Jeff Szer; Andrew Grigg
Neurological events associated with the infusion of cryopreserved bone marrow and/or peripheral blood progenitor cells.
Bone marrow transplantation 2000;25(12):1285-7.
2000: C B Steer; Jeff Szer; J Sasadeusz; Jane P Matthews; Jennifer A Beresford; Andrew Grigg
Varicella-zoster infection after allogeneic bone marrow transplantation: incidence, risk factors and prevention with low-dose aciclovir and ganciclovir.
Bone marrow transplantation 2000;25(6):657-64.
1999: Mark Bentley; Kerry Taylor; Andrew Grigg; H Kronenberg; J Gibson; I Bunce; Paul Eliadis; T Olsen; Susan Wright; D Taylor; Robyn Rodwell
Long-term interferon-alpha 2A does not induce sustained hematologic remission in younger patients with essential thrombocythemia.
Leukemia & lymphoma 1999;36(1-2):123-8.
1999: Andrew Grigg; J F Seymour; A Roberts; Jeff Szer
Mini-allografts' for haematological malignancies: an alternative to conventional myeloablative marrow transplantation.
Australian and New Zealand journal of medicine 1999;29(3):308-14.
1999: James Morton; PN Mollee; Kerry Taylor; Andrew Grigg; Simon Durrant; D Moore; Robyn Rodwell; Paul Eliadis; Cheryl Hutchins; B Williams; G Seeley; Susan Wright; Cathryn Kelly; A Rentoul; H Iland; K Atkinson; H Januszewicz; I Bunce; John Bashford; C Stewart; D Taylor
Safe mobilization of normal progenitors in advanced chronic myeloid leukemia with intensive chemotherapy and granulocyte-colony stimulating factor.
Leukemia research 1999;23(2):177-83.
1999: Richard de Boer; L Kiers; Andrew Grigg
Natural killer cell lymphoproliferative disease associated with combined peripheral and autonomic neuropathy.
Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia 1999;6(1):61-3.
1999: Andrew Grigg; Peter Bardy; K Byron; J F Seymour; Jeff Szer
Fludarabine-based non-myeloablative chemotherapy followed by infusion of HLA-identical stem cells for relapsed leukaemia and lymphoma.
Bone marrow transplantation 1999;23(2):107-10.
1998: Jeff Szer; Andrew Grigg; D Lee; Peter Bardy
HLA-identical sibling peripheral blood cell transplants. The Australian experience and preliminary results of a randomised study.
Bone marrow transplantation 1998;21 Suppl 3():S57-8.
1998: Andrew Grigg; B Tait; Stephen Davis; L Kiers
Association of acute inflammatory demyelinating polyneuropathy with acute lymphoblastic leukaemia and HLA-A11.
Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia 1998;5(2):169-71.
1998: Andrew Grigg; R Chapman; Jeff Szer
Fatal CMV pneumonia associated with steroid therapy after autologous transplantation in patients previously treated with fludarabine.
Bone marrow transplantation 1998;21(6):619-21.
1997: R Abraham; Jeff Szer; Peter Bardy; Andrew Grigg
Early cyclosporine taper in high-risk sibling allogeneic bone marrow transplants.
Bone marrow transplantation 1997;20(9):773-7.
1997: Ian Nicholson; Mike Varney; C Kanaan; Andrew Grigg; J Szer; K Tiedemann; Brian D Tait
Alloresponses to HLA-DP detected in the primary MLR: correlation with a single amino acid difference.
Human immunology 1997;55(2):163-9.
1997: G Goss; Jeff Szer; Russell L Basser; R Fox; Andrew Grigg
Multiple cycles of aggressive chemotherapy prior to autologous peripheral stem cell transplantation for lymphoma.
Australian and New Zealand journal of medicine 1997;27(3):323-9.
1997: Andrew Grigg; J Morton; S Durrant; Peter Bardy; Jeff Szer
Factors influencing the outcome of donor marrow transplantation in adults from less than ideal donors: experience from two Australian centres.
Australian and New Zealand journal of medicine 1997;27(3):311-8.
1997: Andrew Grigg; M H Harun; Jeff Szer
Variability in determination of body weight used for dosing busulphan and cyclophosphamide in adult patients: results of an international survey.
Leukemia & lymphoma 1997;25(5-6):487-91.
1997: Timothy P Hughes; Andrew Grigg; Jeff Szer; J Ho; D Ma; B M Dale; R M Green; J E Norman; RE Sage; Richard Herrmann; Paul Cannell; Anthony P Schwarer; Kerry Taylor; K Atkinson; Chris Arthur
Mobilization of predominantly Philadelphia chromosome-negative blood progenitors using cyclophosphamide and rHUG-CSF in early chronic-phase chronic myeloid leukaemia: correlation with Sokal prognostic index and haematological control.
British journal of haematology 1997;96(3):635-40.